Who is at risk?

After children aged 4 years and under, **adolescents and young adults aged 15 to 24 years** have the highest rates of reported IMD in Canada.

IMD has historically occurred in:

- Schools
- Colleges
- > Camps
- Other places where there are large numbers of teens and young adults

Meningococcal meningitis can be vaccine-preventable, but...

...routine childhood vaccination programs only cover IMD vaccinations for 4 of the 5 common serogroups:

• They do not include vaccination for serogroup B

47[%] All other serogroups

> Serogroup B 53[%]

Serogroup B is the most common cause of IMD in Canadian adolescents and young adults aged 10-25 years old (2013–2017)

Already vaccinated against meningococcal meningitis?



Ask your healthcare professional about vaccination with TRUMENBA, for 10 to 25 year olds.

Although it is impossible to prevent people from sharing germs, vaccination is one of the best ways to help prevent meningitis B.

Like all vaccines, TRUMENBA can cause side effects, although not everybody gets them. The most common side effects (reported in more than 1 in 10 people) after having TRUMENBA include headache, nausea, diarrhea, muscle pain, joint pain, redness, swelling and pain at the injection site, chills and fatigue (tiredness). Other common side effects (in more than 1 in 100 people) after having TRUMENBA are vomiting and fever ≥38°C. Side effects that have been reported during marketed use include allergic reactions and fainting. Tell your healthcare professional if you have, or your child has, a troublesome symptom or side effect not listed here, or one that becomes bad enough to interfere with daily activities.

For more information, please consult the Product Monograph at www.pfizer.ca/pm/en/Trumenba.pdf or call **1-800-463-6001**.

DIN: 02468751







TRUMENBA

4⊢ Trumenba®

Help protect them from the threat of meningitis B.

A vaccine for **meningitis B** prevention

Almost an adult. Always your baby.

TRUMENBA is a vaccine to prevent meningitis B (invasive meningococcal disease caused by *Neisseria meningitidis* serogroup B bacteria), for use in people aged 10 through 25 years.

As with any vaccine, TRUMENBA will not protect 100% of those who receive it.

Your teen may be protected against other forms of meningococcal disease, but vaccines against serogroup B **are not yet part of regular childhood vaccinations.**

Ask your healthcare professional about TRUMENBA and help protect your teen from meningitis B.

Our consumer website is available at Trumenba.ca

What is invasive meningococcal disease (IMD)?

A serious and potentially fatal bacterial infection

IMD is a serious bacterial infection caused by the *N. meningitidis* bacteria, which can lead to dangerous and sometimes fatal diseases including:

- meningitis (inflammation of the lining of the brain and spinal cord), and
 sepsis (blood poisoning)
- Symptoms include: Consequences include: > Sudden fever > Death > Coma > Drowsiness Irritability or agitation Lona-term health problems (in up to > Intense headache 1 in 3 survivors) Nausea and vomitina • Hearing loss > Stiff neck Neurologic disabilities Digit or limb > Light sensitivity amputations





Even when the disease is treated early, 5% to 10% of patients die, typically within 24-48 hours after symptoms start.

How often is IMD caused by serogroup B?

There are 5 serogroups of the *N. meningitidis* bacteria most commonly associated with IMD: A, C, $W_{135'}$ Y and B.

MenB was associated with >60% of cases of IMD in Canadian adolescents and young adults between 2012 and 2016.

TRUMENBA® is a registered trademark of Wyeth LLC, a subsidiary of Pfizer Inc.

How is meningitis **B** spread?

MenB is a serious infection that can be spread through common adolescent and young-adult behaviours.



Quick facts

• Up to 10% of healthy people may carry *N. meningitidis* bacteria without any symptoms.

- Healthy adolescents and young adults are more likely to be carriers of this bacteria.
- The carriage is highest in adolescents and young adults up to 30%.

What is TRUMENBA?

TRUMENBA is a vaccine to help prevent meningitis B (IMD caused by *N. meningitidis* serogroup B bacteria), for use in people aged 10 through 25 years.

IMD is a serious and sometimes life-threatening bacterial infection that can result in meningitis and sepsis.

How does it work?

TRUMENBA targets a protein found in over 95% of bacteria that cause meningitis B. It works by helping the body to make antibodies (the body's natural defences), which protect you or your child against this disease. These antibodies kill the bacteria that cause meningitis B.

If a vaccinated person comes into contact with the bacteria that cause this disease, their body is usually ready to destroy them.

Understanding the different serogroup coverage of meningococcal meningitis vaccines

Your teen may be protected against other forms of meningococcal disease, but vaccines against serogroup B **are not yet part of regular childhood vaccinations.**

A primary vaccine against serogroups ACWY or only serogroup C is given routinely as part of immunization programs in most provinces across Canada, yet...

Not part of the routine immunization program


TRUMENBA Meningococcal B vaccine (MenB)



53[%] of all reported IMD cases (among identified serogroups) in Canada between 2013 and 2017.

How is it given?

Your healthcare professional will inject **TRUMENBA** into your upper arm muscle as a single injection of 0.5 mL, on two or three separate occasions.



It is up to you to ask your healthcare professional about TRUMENBA